![](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/Jan-21-Infographic-Headache-1-scaled.jpg)
Download a PDF of the infographic.
![](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/Jan21-Infographic-Headache-main.jpg)
![](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/Jan21-Infographic-Headache-_Migrane.jpg)
![](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/Jan21-Infographic-Headache-_Medication-overuse.jpg)
![](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/Jan21-Infographic-Headache-_Tension.jpg)
![](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/Jan21-Infographic-Headache-_Cluster.jpg)
![](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/Jan21-Infographic-Headache-_Red-flag.jpg)
Sources: The Migraine Trust, British Association for the Study of Headache (BASH), National Institute for Health and Care Excellence (NICE),
Scottish Intercollegiate Guidelines Network, NHS Rightcare, Lancet Neurol 2018;17:954, Cephalalgia 2014;34:409. Editorial advisers:
Anish Bahra, a consultant neurologist, who runs tertiary headache services at the National Hospital for Neurology and Neurosurgery and Barts Health; Stuart Weatherby, a consultant neurologist, who runs a secondary care headache service at University Hospitals Plymouth NHS Trust; both were authors on the BASH guidelines; Kay Kennis, a GP with a special interest in headache, who sat on the NICE headache guidelines development group.